{"classes":[{"categories":[{"measurements":[{"comment":"The number of events was not sufficient for the estimation of this parameter (i.e. upper limit of the CI)","groupId":"OG000","lowerLimit":"31.8","upperLimit":"NA","value":"44.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"OS was defined as the time from study entry to death from any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle plus Letrozole 2.5 mg administered orally daily for 28 days.","id":"OG000","title":"Ribociclib and Letrozole"}],"paramType":"MEDIAN","populationDescription":"Eligible participants who received any amount of protocol therapy.","reportingStatus":"POSTED","timeFrame":"From date of protocol entry to date of death assessed up to approximately 62 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}